Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: Results from the Canadian 'Treatment of Erectile Dysfunction' observational study

BJU International

Volumn 98, Issue 3, 2006, Pages 623-629

  Lee, Jay ^a,i   Pommerville, Peter ^b   Brock, Gerald ^c   Gagnon, Robert ^d   Mehta, Pravinsagar ^e,f   Krisdaphongs, Michoke ^g   Chan, Melanie ^h   Chan, John ^h   Dickson, Ruth ^h  

^a UNIVERSITY OF CALGARY   (Canada)

^b Can Med Clinical Research Inc   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Clinique de Médecine Familiale de Clermont   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f Laxmi Centre   (Canada)

^g Conception Bay Medical Clinic ^*  (Canada)

^h ELI LILLY AND COMPANY   (United States)

ⁱ Rockyview General Hospital   (Canada)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Preference; Sildenafil; Tadalafil

Indexed keywords

SILDENAFIL; TADALAFIL;

ADULT; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUALITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ATTITUDE OF HEALTH PERSONNEL; CARBOLINES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PATIENT SATISFACTION; PERSONAL SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SEXUAL PARTNERS; TREATMENT OUTCOME;

EID: 33746888237     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06384.x     Document Type: Article

References (34)

1. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6
2. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004; 170: 1429-37
3. Brock G, Casey R, Carrier S. Erectile dysfunction: educational forum - I. Can J Urol 2001; 8: 1416-8
4. Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A, Fernandez A, Burgos R, Rejas J. Male erectile dysfunction and health-related quality of life. Eur Urol 2003; 44: 245-53
5. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997; 9: 141-8
6. Fugl-Meyer K, Fugl-Meyer AR. Sexual disabilities are not singularities. Int J Impot Res 2002; 14: 487-93
7. Chevret M, Jaudinot E, Sullivan K, Marrel A, De Gendre AS. Quality of sexual life and satisfaction in female partners of men with ED: psychometric validation of the Index of Sexual Life (ISL) questionnaire. J Sex Marital Ther 2004; 30: 141-55
8. Nicolosi A, Moreira ED Jr, Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Disord 2004; 82: 235-43
9. Ichikawa T, Takao A, Manabe D et al. The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction. Int J Urol 2004; 11: 755-62
10. Carroll JL, Bagley DH. Evaluation of sexual satisfaction in partners of men experiencing erectile failure. J Sex Marital Ther 1990; 16: 70-8
11. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. The Sildenafil Study Group. N Engl J Med 1998; 338: 1397-404
12. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6
13. Hellstrom WJ, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71
14. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-7
15. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004; 14: 367-73
16. Althof SE, Corty EW, Levine SB et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-9
17. Brock G, Chan J, Salgado L et al. Treatment of erectile dysfunction (TED): Focus on treatment satisfaction of patients and partners. J Sex Med 2006; 3 (Suppl. 3): 212, Abstract
18. Daly LE, Bourke GJ. Interpretation and Uses of Medical Statistics, 5th edn. London: Blackwell Science, 2000: 381-422
19. von Keitz A, Rajfer J, Segal S et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-509
20. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-23
21. Ströberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724-37
22. Eardley I, Mirone V, Montorsi F et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-32
23. Porst H, Kleingam S, Arnds S. The three PDE5 inhibitors sildenafil, tadalafil and vardenafil: results of a comparative preference trial in 222 patients with erectile dysfunction. J Urol 2004; 171 (4 Suppl.): 315, Abstract
24. Sommer F, Mathers M, Klotz T et al. Which PDE5 inhibitor do patients prefer? A comparative study of 50 mg sildenafil, 10 mg tadalafil and 10 mg vardenafil. Eur Urol Suppl 2004; 3: 105
25. Sommer F, Klotz T, Mathers M et al. A comparative randomized multicentre study of the maximum dose of sildenafil, tadalafil and vardenafil. Eur Urol 2004; 3 (Suppl.): 105, Abstract 409
26. Yassin A, Saad F. Comparing the three PDE-5 inhibitors in the same population. Presented at the World Congress of Sexology, Montreal, Canada, July 10-15, 2005, Abstract 1008.3
27. Verheyden B, Van Neyghen I. A head to head study comparing efficacy and tolerance of sildenafil, tadalafil, and vardenafil in patients with ED. J Sex Med 2005; 1 (Suppl.): 21, Abstract
28. Sommer F, Klotz T, Mathers M et al. Which PDE-5 inhibitor do patients prefer? A controlled comparative randomized placebo-controlled multicenter study. J Urol 2004; 171 (Suppl.): Abstract 1192
29. Lue TF, Giuliano F, Montorsi F et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6-23
30. Guay AT, Spark RF, Bansal S et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem - 2003 update. Endocr Pract 2003; 9: 77-95
31. O'Sullivan I, Orbell S, Rakow T, Parker R. Prospective research in health service settings. health psychology, science and the 'Hawthorne' effect. J Health Psychol 2004; 9: 355-9
32. Mangione-Smith R, Elliott MN, McDonald L, McGlynn EA. An observational study of antibiotic prescribing behavior and the Hawthorne effect. Health Serv Res 2002; 37: 1603-23
33. De Amici D, Klersy C, Ramajoli F, Brustia L, Politi P. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials 2000; 21: 103-14
34. Zinman R, Bethune P, Camfield C, Fitzpatrick E, Gordon K. An observational asthma study alters emergency department use: the Hawthorne effect. Pediatr Emerg Care 1996; 12: 78-80